Labeling of A: AT-Muse cells and B: ASCs with antibodies anti- SSEA3, CD45, CD44, CD166 and controls. C: The % of SSEA3+ cells was higher in the AT-Muse group than in the ASCs group. D: Immunofluorescence image confirming the labeling of SSEA3 (green) and DAPI (blue) in AT-Muse cells at P4 in vitro. Scale bar = 100 μm. E: AT-Muse cells were CD166+, CD44+ and CD45- confirming their immunophenotype. F-I: The AT-Muse group showed higher expression of OCT4, NANOG and S1PR2 than the ASCs group. Results are means ± SD. *p<0.05, Mann-Whitney U test.</p
<p>(A/B) Flow cytometric analysis of MSCs; data are presented as Δ Median defined as the mean fluore...
<p>Cells of passage number 12–20 were labeled with PE- or APC-conjugated antibodies against the indi...
<p>(A) Reactivity of mAb and BsAb on hCXCR3 and hCCR6 L1.2 expressing cells. The hCXCR3 and hCCR6 L1...
<p>Panel (a) Schematic of the <i>in vivo</i> and <i>in vitro</i> experiment. Panel (b) CD29, CD31, C...
<p>A significant number of ASCs at day 0 are clearly positive for mesenchymal markers, including CD2...
<p>Flow cytometry histograms from a representative population of passage 2 human ASCs for mesenchyma...
<p>A) Cells were analyzed by flow cytometry for MSC surface markers CD29, Sca1; hematopoietic marker...
<p>(A) Expression of surface markers CD14, CD19, CD34, CD45, HLA-DR, CD73, CD90, CD105 (filled) with...
<p>The percentages of CXCR4-positive cells in DE differentiated SNL-201B7 (A) and -253G1 (B) or MEFP...
<p>GBM8401 SP and non-SP cells were sorted and then incubated with specific anti-CD marker antibodie...
<p>The percentages of CXCR4-positive cells (n = 6 each) were analyzed by flow cytometry. Mouse IgG2a...
Antigen expression patterns of the four cell lines with an immortalization potential (SIBC62, SIBC12...
<p>Sixth passage, 70% confluence Ad-MSC, were labeled with monoclonal antibodies and analyzed by flo...
<p>(A). Representative flow cytometry of WJ-MSCs (n = 3). Cells express CD29, CD44, CD73, CD90, CD10...
<p>The cells were positive for CD105 (97.3%) and CD44 (99%), but negative for CD34 (2.8%), CD31 (2.1...
<p>(A/B) Flow cytometric analysis of MSCs; data are presented as Δ Median defined as the mean fluore...
<p>Cells of passage number 12–20 were labeled with PE- or APC-conjugated antibodies against the indi...
<p>(A) Reactivity of mAb and BsAb on hCXCR3 and hCCR6 L1.2 expressing cells. The hCXCR3 and hCCR6 L1...
<p>Panel (a) Schematic of the <i>in vivo</i> and <i>in vitro</i> experiment. Panel (b) CD29, CD31, C...
<p>A significant number of ASCs at day 0 are clearly positive for mesenchymal markers, including CD2...
<p>Flow cytometry histograms from a representative population of passage 2 human ASCs for mesenchyma...
<p>A) Cells were analyzed by flow cytometry for MSC surface markers CD29, Sca1; hematopoietic marker...
<p>(A) Expression of surface markers CD14, CD19, CD34, CD45, HLA-DR, CD73, CD90, CD105 (filled) with...
<p>The percentages of CXCR4-positive cells in DE differentiated SNL-201B7 (A) and -253G1 (B) or MEFP...
<p>GBM8401 SP and non-SP cells were sorted and then incubated with specific anti-CD marker antibodie...
<p>The percentages of CXCR4-positive cells (n = 6 each) were analyzed by flow cytometry. Mouse IgG2a...
Antigen expression patterns of the four cell lines with an immortalization potential (SIBC62, SIBC12...
<p>Sixth passage, 70% confluence Ad-MSC, were labeled with monoclonal antibodies and analyzed by flo...
<p>(A). Representative flow cytometry of WJ-MSCs (n = 3). Cells express CD29, CD44, CD73, CD90, CD10...
<p>The cells were positive for CD105 (97.3%) and CD44 (99%), but negative for CD34 (2.8%), CD31 (2.1...
<p>(A/B) Flow cytometric analysis of MSCs; data are presented as Δ Median defined as the mean fluore...
<p>Cells of passage number 12–20 were labeled with PE- or APC-conjugated antibodies against the indi...
<p>(A) Reactivity of mAb and BsAb on hCXCR3 and hCCR6 L1.2 expressing cells. The hCXCR3 and hCCR6 L1...